🇺🇸 FDA
Pipeline program

RTA 408 Capsule, 10 mg, Skyclarys 50 mg hard capsules, RTA 408 Capsule, 2.5 mg, Skyclarys 50 mg hard capsules

408-C-1402

Phase 2 small_molecule active

Quick answer

RTA 408 Capsule, 10 mg, Skyclarys 50 mg hard capsules, RTA 408 Capsule, 2.5 mg, Skyclarys 50 mg hard capsules for Friedreich's ataxia is a Phase 2 program (small_molecule) at Lacuna Pharma Pty Ltd with 1 ClinicalTrials.gov record(s).

Program details

Company
Lacuna Pharma Pty Ltd
Indication
Friedreich's ataxia
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials